Page last updated: 2024-08-16

zonisamide and safinamide

zonisamide has been researched along with safinamide in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's4 (100.00)2.80

Authors

AuthorsStudies
Bhowmick, SS; Fox, SH; Gonzalez-Latapi, P; Saranza, G1
Jing, XZ; Luo, X; Wang, XP; Yuan, XZ; Zhang, SY1
Cai, G; Cai, H; Cui, Y; Feng, T; Lin, F; Su, D; Yan, R1
Abou-Setta, A; Aboulatta, L; Askin, N; Eltonsy, S; Haidar, L; Lavu, A; Peymani, P; Rabbani, R; Zarychanski, R1

Reviews

4 review(s) available for zonisamide and safinamide

ArticleYear
Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update.
    CNS drugs, 2020, Volume: 34, Issue:10

    Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Drug Development; Drug Repositioning; Humans; Parkinson Disease; Purines; Zonisamide

2020
An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.
    Current neuropharmacology, 2023, Volume: 21, Issue:8

    Topics: Antiparkinson Agents; Dopamine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Serotonin; Zonisamide

2023
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
    European journal of neurology, 2023, Volume: 30, Issue:4

    Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Network Meta-Analysis; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Zonisamide

2023
Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    CNS drugs, 2023, Volume: 37, Issue:11

    Topics: Adult; Dopamine Agents; Humans; Monoamine Oxidase; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Zonisamide

2023